IQ MPS
IQ Microphysiological Systems Affiliate
An Affiliate of the International Consortium for Innovation and Quality in Drug Development
Module I Summary
This session will cover the functional readouts and reference ranges for key liver complex in vitro model parameters. We will introduce relevant COUs and highlight liver MPS model characterization and proof-of-concept data for DMPK and safety testing. Additionally, the value of liver MPS in replicating species-specific toxicity that was not reproducible using traditional in vitro systems (i.e., 2D plated hepatocytes) will be discussed.
Date & Time
Monday, December 4, 2023 at 1:00 pm ET
Duration
90 minutes
Agenda
Welcome and Introduction
Aaron Fullerton, Genentech
Lessons from Module I Sessions 1-3 (Introduction to CIVM/MPS and Technical Considerations for Experiemental Design)
Jason Ekert, UCB
Rhiannon David, Astrazeneca,
Tom Chan, BMS
James Gosset, Pfizer
Q&A / Discussion
Deidre Dalmas Wilk, GSK
Lessons from Module I Sessions 4-5 (Leveraging MPS Data for In Silico Modeling and CIVM/MPS Qualification Considerations)
Dave Stresser, AbbVie
Aaron Fullerton, Genentech
Q&A / Discussion
Deidre Dalmas Wilk, GSK
Module I Closing Remarks
Nakissa Sadrieh, FDA
Introduction to Module II: Established CIVM/MPS (Organ-Specific Sessions)
Deidre Dalmas Wilk, GSK
Moderators and Presenters
